GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK pursues co-administration of RSV and shingles vaccines
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new hope.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial showed that co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ produced a non-inferior immune response and was well tolerated.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
Flu, RSV and shingles could be problematic for some older adults
Respiratory syncytial virus (RSV) is a common virus that usually causes mild, cold-like symptoms. You may have heard of ...
5 Vaccines You Need After 50: These Shots Can Help Protect Against Illnesses as You Get Older
Closer takes a look at five vaccines you should get after you turn 50 to help protect against illness. Shingles: “The first ...
Sarnia Observer16d
LETTER: Some seniors paying out of pocket for shingles vaccines
A shingles infection can be very serious and may lead to complications such as loss of vision and debilitating nerve pain. The commercials go out to tell us that 99 per cent of adults 50 years or ...
Gazeta.pl on MSN1d
A Vaccine Against an Infectious Disease Protects Against Dementia? "Intriguing"
The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...